BridgeLine Translational Partners
Preclinical Strategy Built to Survive Diligence and Accelerate the Path to the Clinic
We build the study-by-study roadmap from discovery through IND-enabling — anchored in unmet need, designed for regulatory alignment, and packaged to answer every question investors and pharma partners will ask.
Complimentary. 30 minutes. No obligation.
What a Development Plan Covers
From discovery biology through diligence-ready deliverables, in one integrated plan.
Unmet Need & Positioning
Where does your program fit? Target rationale, indication selection, competitive landscape, and the strategic case for development.
Preclinical Roadmap
Study-by-study plan: models, endpoints, success criteria, timelines, budgets, and CRO recommendations. From current data through IND-enabling.
Path to Clinic
IND/CTA strategy, dose rationale, regulatory alignment, and a clear outline of the nonclinical submission package. The regulatory path that gets you to the clinic.
Diligence-Ready
Risk registers, gap analysis, visual timelines, and board-ready deliverables. Packaged for investor presentations, data rooms, and diligence calls.
How to Start
Every engagement begins with a Strategy Call. Most companies start with a Diagnostic or go directly to a Roadmap.
Strategy Call
Complimentary · 30 minutes
Tell us about your program, your stage, and the decisions you're facing. We'll assess whether a Diagnostic or a full Roadmap is the right starting point.
Strategy Diagnostic
1-2 weeks
A focused assessment of where your program stands: preclinical readiness, competitive positioning, and strategic gaps. Tells you exactly what to prioritize next.
Preclinical Roadmap
2-4 weeks · The signature engagement
Unmet need analysis, study-by-study preclinical plan, path to clinic, and everything packaged for investor and partner diligence.
Who We Work With
Early-stage biotech companies building preclinical programs in gene therapy, RNA therapeutics, biologics, and related modalities.
Built with an Operator-to-Acquirer Lens
BridgeLine combines hands-on execution experience with acquirer-side diligence perspective.
Timothy S. Luongo, PhD, MSTR
Founder and Principal
Experience spans Cephalon (now Teva), Sarepta Therapeutics, Spark Therapeutics (Roche), StrideBio, and the NIH. Designed and executed IND-enabling preclinical programs across gene therapy, RNA therapeutics, and biologics. Evaluated companies as acquisition/partnership targets and supported diligence on transactions valued up to $11B. PhD from Temple University. Master of Science in Translational Research (Regulatory Affairs and Drug Development) from UPenn. BS in Biochemistry from Eastern University. High-impact publication record including Nature, Cell, Immunity, and Circulation.
View LinkedIn ProfileTrusted by Leaders
Endorsements on rigor, decision quality, and execution.
“In my time working with Tim at Spark Therapeutics, he stood out for his ability to quickly identify what mattered most to reduce risk and keep teams focused on the highest-impact work. He translates complex data into clear priorities, crisp recommendations, and actionable next steps. He's highly collaborative and raises the quality of decision-making across functions. I would strongly recommend BridgeLine to any biotech building toward a key inflection point.”
Christopher Rilling, PhD
VP of Science, Parallel Bio
Ready to Build a Plan That Holds Up?
Book a Strategy Call. Complimentary, 30 minutes, no obligation. We'll discuss your program and recommend the right starting point.
Book a Strategy Call30-minute call · No obligation · Confidential
info@bridgelinetranslational.com · bridgelinetranslational.com